"Mutation Status of KRAS, BRAF, PIK3CA and Expression Level of AREG and EREG Identify Responders to Cetuximab in a Large Panel of Patient Derived Colorectal Carcinoma Xenografts of All Four UICC Stages"
written by Anatole A. Klyosov, Igor L. Rozhanskii,
published by Journal of Cancer Therapy, Vol.4 No.2, 2013
has been cited by the following article(s)：
Regorafenib (BAY 73‐4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
International Journal of Cancer 2014
Predictive In Vivo Models for Oncology
New Approaches to Drug Discovery 2015